Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people.

  title={Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people.},
  author={Vassiliki M. Cartsos and Shao Zhu and Athanasios I. Zavras},
  journal={Journal of the American Dental Association},
  volume={139 1},
BACKGROUND While osteonecrosis of the jaw (ONJ) has been associated with the prolonged use of bisphosphonates (BPs), there is limited information about the risk of ONJ among users of oral BPs or about the magnitude of the risk among users of intravenous (IV) BPs. METHODS The authors studied medical claims data from 714,217 people with osteoporosis or cancer to identify diagnostic codes or procedure codes for three outcomes: inflammatory conditions of the jaws, including osteonecrosis; major… 

Tables from this paper

Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies

The available evidence suggests that use of BPs in cancer patients is associated with a substantial risk for ONJ, and patients receiving IV BP are at the highest risk.

Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges

The literature suggests a broad range of possible values for the prevalence of BONJ; the estimate fell within the range from prior literature.

Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases

Irrespective of race, elderly women undergoing steroid therapy have an increased incidence of BRONJ even with oral administration of bisphosphonate, and this medication is relatively safe and effective in preventing complications of osteoporosis.

Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.

Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw: Focus on Risk, Prevention and Treatment.

This review discusses current issues in BROMJ, with a focus on risk, prevention and treatment, and reconsiders the definition of BRONJ from the standpoint of clinical evidence.

The impact of bisphosphonates on oral health: lessons from the past and opportunities for the future

  • A. Zavras
  • Medicine
    Annals of the New York Academy of Sciences
  • 2011
The state of knowledge about the impact of bisphosphonates on oral health is reviewed critically, using the principles of epidemiology, to identify scientific gains, research challenges, and future research opportunities on the topic.

Oral bisphosphonates and the risk for osteonecrosis of the jaw.

Primary care physicians treating bone diseases with bisphosphonate need to be aware of this potential risk and plan the prophylaxis, early diagnosis and prevention of potential consequences, with particular focus on systemic and local predisposing pathologies.

Bisphosphonate adverse effects, lessons from large databases

Compared with the reduction in classical osteoporotic fractures, the risk of harm caused by bisphosphonates is low, according to information presently available from clinical trials and from health databases, however, database studies have limited specificity and sensitivity for atypical fractures and ONJ.

Dental extraction as a risk factor for bisphosphonate related osteonecrosis of the jaw in cancer patients: an update.

There is a plausible relationship between dental extractions and the development of BRONJ in cancer patients, and written informed consent must be obtained prior to dental procedures in patients at risk for developingBRONJ.



Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?

  • A. ZavrasShao Zhu
  • Medicine
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • 2006

Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis.

Users of intravenous bisphosphonates had an increased risk of inflammatory conditions, osteomyelitis, and surgical procedures of the jaw and facial bones, and the risk of each outcome increased as cumulative dose increased.

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws

Osteonecrosis of the jaws is strongly associated with the use of aminobisphosphonates, and the mechanism of disease is probably severe suppression of bone turnover, and possible mechanisms of etiopathogenesis are suggested.

A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma

A reduced schedule of ZA may be safer than the standard schedule while maintaining anti-resorptive efficacy and preventing osteonecrosis of the jaw in patients treated only with pamidronate.

Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis

The length of exposure to zoledronate was associated with an increased frequency of ONJ in prostate cancer patients and a possible role of chemotherapy with docetaxel as a cofactor for ONJ merits further evaluation.

Bisphosphonates and osteonecrosis of the jaws.

  • A. Mariotti
  • Medicine, Biology
    Journal of dental education
  • 2008

Bisphosphonates and Osteonecrosis of the Jaws

A review of current data related to the occurrence, risk, prevention, treatment, and management of bisphosphonates-associated osteonecrosis (BON).

Bisphosphonates and jaw osteonecrosis: The UAMS experience